MedPath

Spinraza

These highlights do not include all the information needed to use SPINRAZA safely and effectively. See full prescribing information for SPINRAZA. SPINRAZA (nusinersen) injection, for intrathecal useInitial U.S. Approval: 2016

Approved
Approval ID

dd70cd5f-b0fc-4ba4-a5ea-89a34778bd94

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 24, 2023

Manufacturers
FDA

Biogen

DUNS: 121376230

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Nusinersen

PRODUCT DETAILS

NDC Product Code64406-058
Application NumberNDA209531
Marketing CategoryC73594
Route of AdministrationINTRATHECAL
Effective DateDecember 21, 2022
Generic NameNusinersen

INGREDIENTS (8)

NusinersenActive
Quantity: 2.4 mg in 1 mL
Code: 5Z9SP3X666
Classification: ACTIB
Sodium phosphate, monobasic, dihydrateInactive
Quantity: 0.05 mg in 1 mL
Code: 5QWK665956
Classification: IACT
Sodium phosphate, dibasic, anhydrousInactive
Quantity: 0.10 mg in 1 mL
Code: 22ADO53M6F
Classification: IACT
Sodium ChlorideInactive
Quantity: 8.77 mg in 1 mL
Code: 451W47IQ8X
Classification: IACT
Potassium ChlorideInactive
Quantity: 0.22 mg in 1 mL
Code: 660YQ98I10
Classification: IACT
Magnesium chlorideInactive
Quantity: 0.16 mg in 1 mL
Code: 02F3473H9O
Classification: IACT
WaterInactive
Code: 059QF0KO0R
Classification: IACT
Calcium chlorideInactive
Quantity: 0.21 mg in 1 mL
Code: M4I0D6VV5M
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Spinraza - FDA Drug Approval Details